Roche will accelerate Actemra’s Phase III trial in COVID-19 patients with $25 million in support from the U.S. Biomedical Advanced Research and Development Authority (BARDA). Actemra/RoActemra (tocilizumab), an anti-IL-6 receptor biologic currently approved to treat rheumatoid arthritis, is being evaluated in a randomized, double-blind, placebo-controlled Phase III trial in collaboration with BARDA, for safety and efficacy in hospitalized patients with severe COVID-19 pneumonia compare...